

Appl. No. : 10/649,480
Filed : August 27, 2003

REMARKS

In response to the restriction requirement set forth in the communication, Applicant elects to prosecute Group I, Claims 2-34, drawn to a method of revascularizing an ischemic region with FGF-1. Applicants have cancelled claim 35 corresponding to Group II. Claim 28 has been amended to correct antecedent basis. Claim 36 is added. Support for claim 36 is found in paragraphs 0032 and 0101 of the present specification.

In response to the election of species requirement, Applicants elect the 141 amino acid form of FGF shown as SEQ ID NO: 7 (species G). Note that this protein species corresponds to the DNA sequence SEQ ID NO: 6 (species F). Claims 1, 2 (through SEQ ID NO: 6), 3-15, 17, 20-34 and new claim 36 read upon the elected species. This election is made with traverse. As the Group II claim has been cancelled, only Group I remains. Accordingly, there cannot be a linking claim. Applicants respectfully request examination of all of claims 1-34, and 36, at least with respect to the elected species.

This election is made without prejudice or disclaimer. Applicant reserves the right to pursue the remaining claims in a divisional application.

Conclusion

Should there be any questions concerning this application, the Examiner is invited to contact the undersigned agent at the telephone number appearing below. Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 13, 2005

By: Che S. Chereskin
Che Swyden Chereskin
Registration No. 41,466
Agent of Record
Customer No. 20,995